Navigation Links
Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal

PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR) announced the publication in the Proceedings of the National Academy of Sciences (PNAS), the scientific journal of the NAS, of the first non-human primate study to use multiple, systemic dosing with Calando's lead siRNA therapeutic candidate that is a nanoparticle containing non-chemically modified siRNA and a transferrin protein targeting agent.

The paper, entitled "Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA," was published online in the Early Edition of the PNAS. This paper details the results of a pilot safety study of Calando's lead siRNA-containing nanoparticle formulation (CALAA-01) in monkeys. In this dose-escalation experiment, systemically-administered nanoparticles were well-tolerated at doses significantly above those that had been previously shown to be efficacious with a similar formulation in murine cancer models. Overall, this study shows that multiple, systemic doses of CALAA-01 can safely be administered to non-human primates, and is the first example of multiple systemic dosing of siRNA in monkeys.

The formulation investigated contains Calando's proprietary delivery technology with a non-chemically modified siRNA duplex targeting the M2 subunit of ribonucleotide reductase, a well-established cancer target. This duplex, developed by Calando, demonstrates potent anti-proliferative activity across multiple types of cancer in vitro and in vivo. The objective of this escalating-dose pilot study was to assess numerous safety-related parameters for this formulation in non-human primates since it is known that proper evaluation of complement activation is best performed in this type of animal prior to
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
2. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
3. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
4. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
5. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/1/2014)... Aspire Technology Partners (Aspire) announced today that it has achieved ... recognizes Aspire for delivering outstanding customer service to customers in ... "Achieving exceptional results for our customers is core to ... CEO of Aspire. "We are pleased Cisco has recognized our ... are proud to be part of the Cisco channel." ...
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
(Date:8/1/2014)... Aug. 1, 2014 Arena Pharmaceuticals, Inc. ... corporate update and reported financial results for the ... "We have continued to see encouraging advancements ... 43% quarter-over-quarter increase in estimated total prescriptions and ... mark," said Jack Lief, Arena,s President and Chief ...
Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
... DALLAS, June 23, 2011 , - ReportsnReports ... and,Combination Therapies , Report in its store ... Combination,Therapies , Report now! Search 75000+ ... , Pharmaceuticals Market Research Reports Report ...
... Inc., a privately held biotechnology company that develops immunotherapeutics ... announced that 1-year data from Protege, the Company,s Phase ... patients, will be presented at the American Diabetes Association,s ... June 28, 2011 at 9:10 a.m. PDT. ...
Cached Medicine Technology:ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies 2ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies 3ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies 4MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28 2
(Date:8/1/2014)... New York, New York (PRWEB) August 01, 2014 ... ( http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly ... use of power morcellators in gynecological surgeries, Bernstein Liebhard ... decision to withdraw a number of power morcellators marketed ... to a report from The New York Times, some ...
(Date:8/1/2014)... and the benefits of a cancer diagnosis may improve ... a study conducted by a researcher at the University ... an expressive writing intervention is the writing instruction. Otherwise, ... events. Writing a journal can be therapeutic, but oftentimes ... it,s effective or not," said Qian Lu, assistant professor ...
(Date:8/1/2014)... DELRAY BEACH, FL (PRWEB) August 01, 2014 ... hosted the 2014 California NextGen User Symposium in San ... event was held at the JW Marriott Union Square ... to help practices get up to speed with ACA ... said earlier this month. The symposium provides attendees guidance ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
(Date:8/1/2014)... (BRONX, NY) Scientists at Albert Einstein ... that bacteria that aid in digestion help keep the ... journal Immunity , could yield new therapies for ... other disorders. , The research involved the intestinal microbiome, ... these microorganisms in promoting or preventing disease is a ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:'Normal' bacteria vital for keeping intestinal lining intact 2
... Study found higher levels of staph, E. coli in ... News) -- Could common bacterial infections cause some cases of sudden ... of a study in this week,s issue of The Lancet ... levels of Staphylococcus aureus and Escherichia coli ...
... 29 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... joined the company as Vice President, International ... the development and,execution of clinical and regulatory ... candidates. Dr. Clarke was most recently,Vice President, ...
... MATK ) announced today that it will be ... Medical Technology,Conference in New York. The conference is being ... Palace Hotel. Peter L. Buzy, CFO is scheduled to ... Time., A live audio webcast of Martek,s presentation ...
... Ltd.,(Nasdaq: EMITF ) ("EI" or the "Company") today ... Loss for the first quarter of 2008 amounted to ... of NIS 27.3 million,(approximately US$ 7.7 million) is attributable ... NIS 23.8 million (approximately US$ 6.7,million) is attributable to ...
... the continued presence of a doula an experienced non-medical ... beneficial effects for middle- and upper-class women in childbirth, even ... with them, according to a new study in the journal ... of 420 pregnant women in their third trimester were randomized ...
... A critical enzyme used to prepare a powerful ... better target the cells the natural product attacks, according ... the Journal of Biological Chemistry. , Building on their ... Boston College and the University of Wisconsin, Madison discovered ...
Cached Medicine News:Health News:Bacterial Infection May Boost SIDS Risk 2Health News:Bacterial Infection May Boost SIDS Risk 3Health News:Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations 2Health News:Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations 3Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 2Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 3Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 5Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 6Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 7Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 8Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 9Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 10Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 11Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 12Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 13Health News:Enzyme may hold key to improved targeting of cancer-fighting drugs 2
... bring a new standard in the field of ... Labs. Made of medical grade silicone, these durable ... a high level of flexibility while maintaining correct ... available in varying stiffnesses. Lengths are determined by ...
... primary objective of the BioPro Toe implant ... will relieve pain and restore motion while ... undisturbed. The procedure used to implant the ... resection. , ,The design for the great ...
Ad-Techs Spinal Electrodes are intended for intraoperative monitoring of Evoked Potentials (EPs) of the descending pathway during spinal surgery. They are offered with 2 or 3 platinum contacts....
... of Ad-Techs products, our Sphenoidal Electrodes are manufactured ... available in stainless steel or platinum and feature ... (70 mm) long, 21 gauge (0.83 mm) introducing ... as kits or sets. You can also choose ...
Medicine Products: